Neisseria meningitidis Tetravalent Antibodies (Serogroups A, C, W-135 and Y), IgG
Use to assess immunocompetence following Neisseria meningitidis vaccination. To assess suspected immunodeficiency, use pre- and postvaccination serology. Do not use for diagnosis of infection or serotyping.
Quantitative Multiplex Bead Assay
New York DOH Approval Status
Serum separator tube.
Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.2 mL)
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
N. meningitidis A, C, W-135 and Y, IgG:
0.9 µg/mL or less: Antibody concentration not protective.
1.0-2.0 µg/mL: Equivocal.
2.1 µg/mL or greater: Antibody to Neisseria meningitidis detected. Suggestive of protection.
Responder status is determined according to the ratio of the one month post-vaccination concentration to pre-vaccination concentration of IgG antibodies to N. meningitidis (Types A, C, Y, and W-135) as follows:
1. If the one month post-vaccination concentration is less than 3.0 µg/mL, the patient is considered to be a non-responder.
2. If the one month post-vaccination concentration is greater than or equal to 3.0 µg/mL, a patient with a ratio of greater than or equal to 4 is a good responder, a ratio of 2-4 is a weak responder, and a ratio of less than 2 is considered a non-responder
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2001604||N.meningitidis Type A IgG||28546-0|
|2001605||N.meningitidis Type C IgG||28547-8|
|2001606||N.meningitidis Type Y IgG||60466-0|
|2001607||N.meningitidis Type W-135 IgG||60465-2|
- Meningococcal IgG Vaccine Response
- N. Meningitidis IgG Vaccine Response
- Neisseria meningitidis
- Vaccine Response